Entact Bio
Watertown
About Entact Bio
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $121.3M
- Last round: Series Unknown (Jan 2024)
- Website: entactbio.com
- Phone: +1 617 674 5100
Industries & Categories
Biopharma, Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/entact-bio-69833 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.